Table 3.
The prognostic value of SII for OS in cancer patients treated with ICIs.
| Subgroups | No. of studies | No. of patients | Effects model | HR (95%CI) | p | Heterogeneity I2 (%) Ph |
|
|---|---|---|---|---|---|---|---|
| Overall | 13 | 1,758 | Random | 2.62(1.76–3.90) | <.001 | 88.5 | <0.001 |
| Study design | |||||||
| Prospective | 3 | 625 | Fixed | 2.66(2.09–3.39) | <.001 | 0 | 0.702 |
| Retrospective | 10 | 1,133 | Random | 2.62(1.64–4.18) | <.001 | 82.7 | <0.001 |
| Sample size | |||||||
| <100 | 5 | 267 | Fixed | 2.53(1.80–3.56) | <.001 | 0 | 0.413 |
| ≥100 | 8 | 1,491 | Random | 2.46(1.50–4.03) | <.001 | 91.0 | <0.001 |
| Study centre | |||||||
| Single centre | 8 | 905 | Random | 2.76(1.56–4.86) | <.001 | 82.0 | <0.001 |
| Multicentre | 5 | 853 | Fixed | 2.58(2.09–3.19) | <.001 | 0 | 0.841 |
| TNM stage | |||||||
| III–IV | 6 | 751 | Fixed | 2.60(2.01–3.36) | <.001 | 32.8 | 0.190 |
| IV | 7 | 1007 | Random | 2.18(1.30–3.65) | .003 | 88.9 | <0.001 |
| ICIs type | |||||||
| Anti-PD-1 | 8 | 1117 | Random | 2.45(1.47–4.09) | .001 | 89.0 | <0.001 |
| Anti-PD-1/PD-L1 | 1 | 41 | – | 1.99(1.23–3.22) | .005 | – | – |
| Anti-PD-1/PD-L1 + Anti-CTLA-4 | 2 | 290 | Fixed | 3.24(1.81–5.78) | <.001 | 35.4 | 0.213 |
| Anti-PD-1 + Anti-CTLA-4 | 1 | 43 | – | 6.91(0.87–55.05) | .068 | – | – |
| Anti-PD-L1 | 1 | 267 | – | 2.45(1.67–3.59) | <.001 | – | – |
| Cut-off value of SII | |||||||
| <800 | 6 | 459 | Fixed | 2.42(1.79–3.26) | <.001 | 28.1 | 0.224 |
| ≥800 | 7 | 1299 | Random | 2.35(1.39–3.96) | .001 | 91.5 | <0.001 |
| Country | |||||||
| Asian | 9 | 1084 | Random | 2.51(1.57–4.02) | <.001 | 83.7 | <0.001 |
| Non-Asian | 4 | 674 | Fixed | 2.69(2.12–3.43) | <.001 | 0 | 0.680 |
| Survival analysis | |||||||
| Univariate | 3 | 211 | Fixed | 2.15(1.48–3.11) | <.001 | 0 | 0.910 |
| Multivariate | 10 | 1547 | Random | 2.85(1.75–4.64) | <.001 | 90.2 | <0.001 |
| Cancer type | |||||||
| NSCLC | 2 | 89 | Random | 3.61(1.20–10.87) | .023 | 57.6 | 0.125 |
| Esophageal cancer | 1 | 69 | – | 2.49(1.24–4.97) | .010 | – | – |
| Gastric cancer | 2 | 245 | Fixed | 1.98(1.31–2.99) | .001 | 0 | 0.964 |
| RCC | 2 | 362 | Fixed | 3.07(2.14–4.40) | <.001 | 0 | 0.436 |
| BTC | 1 | 60 | – | 2.05(1.14–3.68) | .016 | – | – |
| Mixed | 1 | 168 | – | 2.79(1.49–5.21) | .001 | – | – |
| Urothelial carcinoma | 1 | 267 | – | 2.45(1.67–3.59) | <.001 | – | – |
| HCC | 1 | 110 | – | 5.56(1.78–17.38) | .003 | – | – |
| Melanoma | 1 | 266 | – | 1.08(1.05–1.11) | <.001 | – | – |
| Pancreatic cancer | 1 | 122 | – | 8.06(1.71–37.93) | .008 | – | – |
Note: SII: Systemic Immune-Inflammation Index; OS: overall survival; ICIs: immune checkpoint inhibitors; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; BTC: biliary tract cancer; HCC: hepatocellular carcinoma.